Partners – DNDi

DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.

Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:

Royalty-free to ensure the lowest possible price
Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
Worldwide coverage both for R&D and for manufacture
Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)

An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.

Pharmaceuticals
Biotechs
Universities
University “Spin-off”
Research institutes
National Research Centres
NGOs/IOs
PDPs/PPPs
Hospitals
Ministries of Health/Governmental organizations
Contract Research Organizations (CROs)
Platforms and Networks

Pharmaceuticals

AbbVie (USA) Projects: Screening / Lead optimization / Leish H2L / Chagas H2L / AbbV4083 (Tylamac) / Two ‘4-in-1’ LPV/r based FDC granules

Astellas Pharma (Japan) Projects: Screening

AstraZeneca (UK) Projects: Screening / Discovery / Lead optimization/ Leish H2L

Avista Pharma (formerly SCYNEXIS) (USA) Projects: SCYX-7158

Bayer Healthcare (Germany) Projects: Emodepside

Bristol-Myers Squibb (USA) Projects: Screening

Cipla Inc. (India) Projects: Two ‘4-in-1’ LPV/r based FDC granules / LPV/r pellets with dual NRTI FDC / ASMQ

Daiichi Sankyo (Japan) Projects: Screening

Debiopharm (Switzerland) Projects: Discovery

Eisai Co., Ltd. (Japan) Projects: Screening / Discovery / Fosravuconazole / New benznidazole regimens

E.I du Pont Nemours (USA) Projects: Screening

Farmanguinhos (Fiocruz) (Brazil). Projects: ASMQ

GeneDesign Inc. (Japan) Projects: CpG-D35

Gilead Sciences (USA) Projects: Fexinidazole

GlaxoSmithKline (Spain) Projects: Screening / Lead optimization / Leish H2L

GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA). Projects: Screening

Humax Pharmaceutical (Colombia) – Projects: Anfoleish

Janssen (Belgium) – Projects: Screening

LAFEPE (Brazil) Projects: Paediatric dosage form of benznidazole

Mercachem (The Netherlands) Projects: Screening

Merck (USA) – Projects: Screening / Lead optimization / Leish H2L

Merck Serono (Germany) Projects: Screening

Optimed (France) Projects: Fexinidazole-Miltefosine combination

Paladin Labs (Canada) Projects: New VL treatments – Africa

Pharco Pharmaceuticals Inc. (Egypt) Projects: Sofosbuvir/Ravidasvir

Pfizer Ltd. (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles

Sanofi (France) Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L / Fexinidazole

Sanofi and affiliates (France) Projects: ASAQ / Fexinidazole / Screening

Sanofi-Chinoin (Hungary) Projects: Fexinidazole-Miltefosine combination

Sara Pharm (Romania) Projects: DNDi-6148

Shionogi (Japan) Projects: Discovery

Syngene (India) Projects: DNDi-6148

Takeda Pharmaceutical Company Ltd. (Japan) Projects: Screening / Discovery / Aminopyrazoles

Zenufa Laboratories Ltd (Tanzania) Projects: ASAQ

top of the page

Biotechs

Anacor Pharmaceuticals (USA) Projects: Screening / Lead optimization / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / SCYX-7158 / DNDi-6148

Celgene (USA) Projects: Screening / Discovery / Lead optimization

Celgene Global Health (USA) Projects: CGH VL series 1

Evolva (Switzerland) Projects: Discovery

Genzyme (USA) Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.

iThemba Labs (South Africa) Projects: Lead optimization

Polytherics (UK) Projects: Formulation of amphotericin B, in collaboration with Imperial College.

SCYNEXIS Inc. (USA) Projects: Lead optimization / SCYX-1330682 SCYX-1608210 / SCYX-7158

Sequella, Inc. (USA) Projects: Screening

Vertex (USA) Projects: Screening

top of the page

Universities

Addis Ababa University (Ethiopia) Projects: New treatments for HIV/VL co-infection / SSG&PM

Antwerp University (Belgium) Projects: Screening / Lead optimization/ SCYX-1330682 SCYX-1608210

Auckland University (New Zealand) Projects: DNDi-0690 / Lead optimization

Banaras Hindu University, Institute of Medical Sciences (India) Projects: / New treatments for PKDL

Baylor College of Medicine Children’s Foundation (Uganda) Projects: LPV/r pellets with dual NRTI FDC

Bonn University Hospital, Institute of Medical Microbiology, Immunology and Parasitology (Germany) Projects: Screening

Brasilia University (Brazil) Projects: New VL treatments Latin America

Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) Projects: Fexinidazole-Miltefosine combination

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town (South Africa) Projects: Superbooster therapy for HIV/TB co-infection

Federal University of Sergpipe (Brazil) Projects: New VL treatments Latin America

Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) Projects: Lead optimization / Leish H2L / Chagas H2L

Fundação de Apoio Universidade Federalede Sao Paolo (Brazil) Projects: Lead optimization

Gondar University Hospital (Ethiopia) Projects: New treatments for HIV/VL co-infection / SSG&PM

Imperial College (UK) Projects: Formulation of amphotericin B with Polytherics.

Khartoum University, Institute of Endemic Disease (Sudan) Projects: Fexinidazole-Miltefosine combination / new treatments for PKDL / SSG&PM / Fosravuconazole

London School of Hygiene and Tropical Medicine (UK) Projects: Screening / Lead optimization/ Aminopyrazoles / DNDi-5421 DNDi-5610 / VGH VL series 1 / Chagas H2L / Biomarkers / Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / SSG&PM / New VL treatments Asia

London School of Pharmacy (UK) Projects: Formulation of amphotericin B, in collaboration with Imperial College.

Makarere University (Uganda) Projects: Fexinidazole-Miltefosine combination / SSG&PM / MF/PM combination therapy

McGill University (Canada) Projects: Biomarkers

Michigan State University (USA) Projects: Flubendazole Macrofilaricide (Filarial diseases)

Monash University, Centre for Drug Candidate Optimization (Australia) Projects: Lead optimization/ Chagas H2L / Leish H2L

Murdoch University, School of Veterinary and Biomedical Science (Australia) Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization

Montes Claros State University (Brazil) Projects: New VL treatments Latin America

Nagasaki University (Japan) Projects: CpG-D35

Ohio State University (USA) Projects: CpG-D35

Pace University (USA) Projects: SCYX-1330682 SCYX-1608210

Perinatal HIV Research Unit, University of Witswatersrand (South Africa) Projects: Superbooster therapy for HIV/TB co-infection

Piaui Federal University (Brazil) Projects: New VL treatments Latin America

Radboud University Medical Center (The Netherlands) Projects: Fosravuconazole

Stellenbosch University (South Africa) Projects: Superbooster therapy for HIV/TB co-infection

Universidad Autónoma Juan Misael Saracho (Bolivia) Projects: Biomarkers / New benznidazole regimens / Fexinidazole

Universidad Autónoma Juan Misael Saracho (Spain) Projects: New benznidazole regimens / Fexinidazole

Universidade Estadual de Campinas UNICAMP (Brazil) Project: Lead Optimization

Universidad Mayor de San Simon (Bolivia) Projects: Biomarkers

Universidad Peruana Cayetano Heredia (Peru) Projects: New CL combination therapies

Universidad San Martin (Argentina) Projects: Biomarkers

Estadual do Rio de Janeiro (Brazil) Projects: New VL treatments Latin America

University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (Colombia) Projects: Anfoleish / New CL combination therapies

University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) Projects: DNDi-5421 DNDi-5610 / Aminopyrazoles / Lead optimization/ Leish H2L / DNDi-6148 / DNDi-0690 /

University of Campinas, Brazilian Biosciences National Laboratory (Brazil) Projects: Lead optimization/ Chagas H2L

University of Dundee, Drug Discovery Unit (UK) Projects: Screening

University of Nairobi (Kenya) Projects: LPV/r pellets with dual NRTI FDC

University of Osaka (Japan) Projects: CpG-D35

University of Texas at El Paso (USA) Project: Biomarkers

Uppsala University (Sweden) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / new treatments for PKDL

Utrecht University (The Netherlands) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / MF/PM combination therapy

Various academic partners (South Africa and Kenya) Projects: Two ‘4-in-1’ LPV/r based FDC granules

UCSF, University of California, San Francisco (USA) Projects: K777 (Chagas) / RTV Superbooster for HIV/TB co-infection (Paediatric HIV)

University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.

Universidade Ouro Preto (Brazil) Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization

University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK) Projects: ASAQ (Malaria) / ASMQ (Malaria)

University Sains (Malaysia) Projects: ASAQ (Malaria) / ASMQ (Malaria)

top of the page

University “Spin-off”

Epichem (Australia) Projects: Screening / Leish H2L /Chagas H2L / Lead optimization

Eskitis Institute for Cell and Molecular Therapies, Griffith University (Australia) Projects: Lead optimization/ Chagas H2L / Leish H2L

top of the page

Research Institutes

Administración Nacional de Laboratorios e Institutos de Salud (Argentina) Projects: Paediatric dosage form of benznidazole

Broad Institute, MIT and Harvard (USA) Projects: Discovery activity for Chagas disease

CRESIB, Centre de Recerca en Salut Internacional de Barcelona (Spain). Since September 2010, DNDi partner for the clinical phase for Chagas disease. Projects: Azoles E1224 & Biomarker (Chagas)

Dr Mario Fatala Chaben National Institute of Parasitology (Argentina) – Projects: Biomarkers

FIPEC: Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (Argentina) Projects: Clinical studies for Chagas disease.

Georges Institute for International Health (Australia) Projects: ASAQ

Institut de Recherche pour le Développement (France) Projects: SCYX-7158 / Fexinidazole

Institut National de Recherche Biomédicale (DRC) Projects: SCYX-7158 / Fexinidazole

Institute of Tropical Medicine Antwerp (Belgium) Projects: SCYX-7158 / Fexinidazole / New treatments for HIV/VL co-infection / New VL treatments Asia

Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) Projects: New benznidazole regimens / Paediatric dosage form of benznidazole

IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) Projects: ASAQ

IEND, Institute of Endemic Disease, Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) Projects: Fexinidazole (VL) / VL-0208 / SSG&PM (VL in Africa)

Ifakara Health Institute (Tanzania) Projects: ASMQ (Malaria)

IRD, Institut de Recherche pour le Développement (France) Projects: ASAQ (Malaria)

Institut Pasteur (France) Projects: Screening

Institute of Tropical Medicine (Belgium) Projects: VL-0208 / HIV/VL

Kenya Medical Research Institute (Kenya) Projects: Fexinidazole-Miltefosine combination / MF/Paromomycin combination therapy / LPV/r pellets with dual NRTI FDC / SSG&PM

Kononklijk Instituut voor de Tropen (The Netherlands) Projects: Fexinidazole-Miltefosine combination

Medical Research Council (UK) Projects: Two 4-in-1 LPV/r-based fixed-dose combinations (Paediatric HIV)

National Institutes of Health (USA) Projects: Screening / CpG-D35

Necker Institute (France) Projects: Two ‘4-in-1’ LPV/r based FDC granules

Northwick Park Institute for Medical Research (UK) Projects: Screening

Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) Projects: New treatments for PKDL / New VL treatments Asia

Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) Projects: Superbooster therapy for HIV/TB co-infection

The Institut Pasteur (South Korea) Projects: Screening

The Netherlands Cancer Institute (The Netherlands) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection

The Swiss Tropical and Public Health Institute (Switzerland) Projects: Screening / SCYX-7158 / Fexinidazole / NECT / SSG&PM

University of Georgia Research Foundation (USA) Projects: Biomarkers

Walter Reed Army Institute (USA) Projects: Screening

top of the page

National Research Centres

Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) (Argentina) Projects: Clinical trials for Chagas disease.

Barcelona Centre for International Health Research (Spain) Projects: Biomarkers

B.P Koirala Institute of Health Sciences (Nepal) Projects: Clinical trials for visceral leishmaniasis.

CNRFP, Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso) Projects: ASMQ (Malaria)

CDRI, Central Drug Research Institute (India) Projects: VL-2098 / Nitroimidazole backup (VL)

CSIR, Council of Scientific and Industrial Research (India) Projects: Various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.

Erasmus Medical Centre (The Netherlands) Projects: Fosravuconazole

Fiocruz, Fundaçao Oswaldo Cruz (Brazil) Projects: Azoles E1224 & Biomarker (Chagas)

Indian Council of Medical Research (ICMR) (India) Projects: New VL treatments Asia

International Centre for Diarrhoeal Disease Research (Bangladesh) Projects: New treatments for PKDL / New VL treatments Asia

IS Global, Centre de Recerca en Salut Internacional de Barcelona (Spain) Projects: New benznidazole regimens/ fexinidazole

Joint Clinical Research Centre (Uganda) Projects: LPV/r pellets with dual NRTI FDC

Kala Azar Medical Research Centre (India) Projects: New treatments for PKDL / New VL treatments Asia

LNBio/CNPEM (Brazil) Projects: Lead optimization

Medical Research Council (UK) Projects: Two ‘4-in-1’ LPV/r based FDC granules

Mycetoma Research Centre, Soba University Hospital (Sudan) Projects: Fosravuconazole

National Institute for Medical Research (NIMR) (Tanzania) Projects: ASMQ (Malaria)

National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) Projects: Biomarkers

National Vector Borne Disease Control Programme (India) Projects: New VL treatments Asia

Northwick Park Institute for Medical Research (UK) Projects: Screening

Novartis Centre de la Recherche Santé Animale (Switzerland) Projects: Screening

Rene Rachou Research Center – Fiocruz MG (Brazil) Projects: New VL treatments Asia

Seattle Biomedical Research Institute (USA). Projects: Discovery for NTDs.

Texas Biomedical Research (USA) Projects: Biomarkers

top of the page

NGOs/IOs

AEDES, consulting firm for Social and Public health sector (Belgium) Projects: ASAQ (Malaria)

Clinton Access Health Initiative (USA) Projects: LPV/r pellets with dual NRTI FDC

Collective of Applied Studies and Social Development (CEADES) (Bolivia) Projects: Azoles E1224 & Biomarker (Chagas)

Communauté Baptiste du Congo (Democratic Republic of Congo) Projects: Fexinidazole (HAT)

Epicentre (France) Projects: NECT

Epicentre Research Center (Uganda) Projects: LPV/r pellets with dual NRTI FDC

Fundación Mundo Sano and ELEA (Argentina) Projects: New benznidazole regimens / Paediatric dosage form of benznidazole

IDA Foundation (The Netherlands) Projects: VL-0208

i+solutions (The Netherlands) Projects: VL-0208 / SSG&PM (VL for Africa)

Médecins Sans Frontières Projects: ASAQ (Malaria) / Azoles E1224 & Biomarker (Chagas) / Fexinidazole (VL) / HIV/VL / NECT / NECT (HAT) / VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa) / New treatments for HIV/VL co-infection / SSG&PM / Two ‘4-in-1’ LPV/r based FDC granules / Biomarkers / Fexinidazole (Chagas)

Microbial Chemistry Research Foundation (Japan) Projects: Screening

OTECI, Offre Technique d’Etude et de Coopération Internationale (France) Projects: ASMQ

Royal Society of Chemistry (UK): MoU to promote open source discovery.

UNITAID (Switzerland) Projects: Two ‘4-in-1’ LPV/r based FDC granules / Projects: LPV/r pellets with dual NRTI FDC

WHO-TDR: (Switzerland) Projects: ASAQ (Malaria) / ASMQ (Malaria) / New VL treatments (Asia) / Screening / New VL treatments Asia

top of the page

PDPs/PPPs

FIND, Foundation for Innovative New Diagnostics (Switzerland) Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.

Medicines for Malaria Venture (MMV) (Switzerland) Projects: Screening

Novartis Institute for Tropical Diseases (Singapore) Projects: Lead optimization

OWH, Institute for One World Health (USA) Projects: VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa)

TB Alliance (USA) Projects: Nitroimidazole (Chagas) / SCYX-2035811 / VL-2098 / Screening and Lead Optimization / Lead optimization/ DNDi-0690

TI Pharma (The Netherlands) Projects: DNDi partner for discovery activities.

top of the page